Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 clients • 7 examiners • 7 art units • 0 of 7 (0%) have an AI response strategy ready
HelixIP LLP has 7 pending office actions in Biotechnology & Pharmaceuticals and 242 career applications. The profile identifies an active specialized docket within a recorded application history.
The resolved allowance rate is 73.39%, and the average is 3.41 office actions per allowance. These measures provide context on resolved outcomes and the examination activity associated with allowances.
Biotechnology clients can use the profile to frame a focused review of workload and prosecution history. The data does not show how results differ across therapeutic areas or individual matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §112 only | 1 (14%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XING, CHRISTINA ILONA | 1 | 83.0% | +10.9% |
| BAUER, NICOLA MARIA | 1 | 58.7% | +52.1% |
| JACOBSON, MICHELE LYNN | 1 | 28.1% | +33.9% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.8% | +31.5% |
| SPEED, DEQUANTARIUS JAVON | 1 | 70.0% | +69.2% |
| QIAN, CELINE X | 1 | 47.5% | +17.2% |
| JONES-FOSTER, ERICA NICOLE | 1 | 49.4% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570546 | New Microbial Diamine Oxidase Derived from Yarrowia Lipolytica for the Degradation of Biogenic Amines | BERKE-SCHLESSEL, DAVID W | 5d |
| 19203667 | Optical Device for Monitoring the Silver Content of Thin Films | XING, CHRISTINA ILONA | — |
| 18644714 | Sugar-Free Edible Vessel | JACOBSON, MICHELE LYNN | — |
| 18558872 | Methods and Compositions for Improving Carbon Accumulation in Plants | SPEED, DEQUANTARIUS JAVON | — |
| 18260220 | Methods and Compositions for Diagnosing and Treating Rare Genetic DIseases | QIAN, CELINE X | — |
| 18260225 | Methods and Compositions for Making Amide Compounds | JONES-FOSTER, ERICA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18570546 | New Microbial Diamine Oxidase Derived from Yarrowia Lipolytica for the Degradation of Biogenic Amines | BERKE-SCHLESSEL, DAVID W | 5d |
| 19203667 | Optical Device for Monitoring the Silver Content of Thin Films | XING, CHRISTINA ILONA | — |
| 18031981 | MALT1 MODULATORS AND USES THEREOF | BAUER, NICOLA MARIA | — |
| 18644714 | Sugar-Free Edible Vessel | JACOBSON, MICHELE LYNN | — |
| 18558872 | Methods and Compositions for Improving Carbon Accumulation in Plants | SPEED, DEQUANTARIUS JAVON | — |
| 18260220 | Methods and Compositions for Diagnosing and Treating Rare Genetic DIseases | QIAN, CELINE X | — |
| 18260225 | Methods and Compositions for Making Amide Compounds | JONES-FOSTER, ERICA NICOLE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Silverpeutics, Inc. | 1 |
| Rheos Medicines, Inc. | 1 |
| Loliware, Inc. | 1 |
| UNIVERSITÄT HOHENHEIM | 1 |
| David BECKER | 1 |
| Rosebud Biosciences, Inc. | 1 |
| GENOMATICA, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 2877 | 1 |
| 1621 | 1 |
| 1793 | 1 |
| 1651 | 1 |
| 1663 | 1 |
| 1699 | 1 |
| 1656 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19203667 | Optical Device for Monitoring the Silver Content of Thin Films | Silverpeutics, Inc. | XING, CHRISTINA ILONA | 2877 | §103§112 | Non-Final OA | — | Pending | May 09, 2025 |
| 18031981 | MALT1 MODULATORS AND USES THEREOF | Rheos Medicines, Inc. | BAUER, NICOLA MARIA | 1621 | §112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18644714 | Sugar-Free Edible Vessel | Loliware, Inc. | JACOBSON, MICHELE LYNN | 1793 | §102§103 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18570546 | New Microbial Diamine Oxidase Derived from Yarrowia Lipolytica for the Degradation of Biogenic Amines | UNIVERSITÄT HOHENHEIM | BERKE-SCHLESSEL, DAVID W | 1651 | §101§103 | Final Rejection | 5d | Pending | Dec 14, 2023 |
| 18558872 | Methods and Compositions for Improving Carbon Accumulation in Plants | David Becker | SPEED, DEQUANTARIUS JAVON | 1663 | §102§103§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18260220 | Methods and Compositions for Diagnosing and Treating Rare Genetic DIseases | Rosebud Biosciences, Inc. | QIAN, CELINE X | 1699 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
| 18260225 | Methods and Compositions for Making Amide Compounds | Genomatica, Inc. | JONES-FOSTER, ERICA NICOLE | 1656 | §103§112 | Final Rejection | — | Pending | Jun 30, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial73.4% of resolved applications prosecuted by Helixip LLP were allowed, across 242 applications in USPTO records.
3.41 office actions per allowed application on average.
7 pending office actions as of October 2026, for 7 clients, before 7 examiners in 7 art units.
